Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Wound
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseWoundSwiss albinoboth male and female (either sex)n = 60 mice randomised into six groups of ten for the wound stu…Topical application to the wound0.5% and 1.0% w/v extract in solution (CaE 0.5%, CaE 1%) or…Treatment started after wound creation and continued through the healing period
Model: Single full-thickness circular excisional dorsal skin wound of 6 mm diameter created with a biopsy punch under ketamine 90 mg/kg plus xylazine 10 mg/kg intraperitoneal anaesthesia
All extract-treated groups accelerated wound closure relative to the vehicle gel. At day 7 wound contraction was 61% for vehicle, 78% for Fibrinase, 73% for CaE 0.5%, 85% for CaE 1%, 74% for CaG 0.5% and 75% for CaG 1%; by day 14 contraction reached 98-100% in all groups. The 1% extract solution pe…
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.